Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 9, 2012, Pages 561-569

  Claringbold, Phillip G ^a   Price, Richard A ^a   Turner, J Harvey ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Chemotherapy; G1 GEP NETs; Multimodality radionuclide therapy

Indexed keywords

CAPECITABINE; LUTETIUM 177; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ANGINA PECTORIS; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; DOSIMETRY; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MALE; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DACARBAZINE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84868270753     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1276     Document Type: Article

References (30)

1. Modlin IM, Latich I, Kidd M, et al. Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol 2006; 4:526.
2. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebocontrolled double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumour growth in patients with metastatic neuroendocrine midgut tumours: A report from the PROMID Study Group. J Clin Oncol 2009; 27:4656.
3. Reubi JC, Schä r JC, Waser B, et al. Affinity profiles for human somatostatin subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273.
4. Waser B, Tamma ML, Cescato R, et al. Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med 2009;50:936.
5. Kwekkeboom DJ, de Herder WA, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA,-TYR3] octreotate: Toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124.
6. Claringbold PG, Brayshaw PA, Price RA, et al. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2011;38:302.
7. Fine RL, Fogelman DR, Schreibman SM. Effective treatment of neuroendocrine tumours with capecitabine and temozolomide. J Clin Oncol 2005;23(16S Suppl):Abst 4216.
8. Isacoff WH. Temozolomide/capecitabine therapy for metastatic neuroendocrine tumours of the pancreas. J Clin Oncol 2006;24(18S):14023.
9. Strosberg J, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117:268.
10. De Decker M, Turner JH. Automated module radiolabeling of peptides and antibodies with gallium-68, lutetium-177 and iodine-131. Cancer Biother Radiopharm 2012;27:72.
11. Turner JH. Outpatient therapeutic nuclear oncology. Ann Nucl Med 2012;26:289.
12. Mckay E. A software tool for specifying voxel models for dosimetry estimation. Cancer Biother Radiopharm 2003; 18:601.
13. Chiavassa S, Aubineau-Laniece I, Bitar A, et al. Validation of a personalized dosimetric evaluation tool (Oedipe) for targeted radiotherapy based on the Monte Carlo MCNPX code. Phys Med Biol 2006;51:601.
14. NCI Common terminology criteria for adverse events (CTCAE) version 4.03 June 14, 2010.
15. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer 2009;45:228.
16. Wilson E. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 1927;22:209.
17. Newcombe RG. Two-sided confidence intervals for the single proportion: Comparison of seven methods. Stat Med 1998;17:857.
18. Rindi G, Arnold R, Bosman FT, et al. Nomenclature and Classification of Neuroendocrine Neoplasms of the Digestive System. WHO Classification of Tumours of the Digestive System, edition 4. Lyon: IARC, 2010;13.
19. Yao JC, Hassan M, Phan A, et al. One hundred years after ''carcinoid'': Epidemiology of and prognostic factors for neuroendocrine tumours in 35,825 cases in the United States. J Clin Oncol 2008;26:3063.
20. Yao JC, Shah MH, Bohas CL, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:514.
21. Delbaldo C, Faivre S, Dreyer C, et al. Sunitinib in advanced pancreatic neuroendocrine tumors: Latest evidence and clinical potential. Ther Adv Med Oncol 2012;4:9.
22. Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumours: Consensus report of the National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Clin Oncol 2011;29:934.
23. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986.
24. Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009;15:338.
25. Chan JA, Stuart K, Earle CC, et al. Prospective study of Bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 2012;30:2963.
26. Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomized, placebo-controlled, phase 3 study. Lancet 2011;378:2005.
27. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501.
28. Booth CM, Eisenhauer EA. Progression-free survival: Meaningful or simply measurable. J Clin Oncol 2012;30: 1030.
29. Gilles EM. Radiologic reviews: More second guessing from armchairs cannot lead the way. J Clin Oncol 2012; 30:116.
30. Baum RP, Harshad MD, Kulkarni R, et al. Peptides and receptors in image-guided therapy: Theranostics for neuroendocrine neoplasms. Semin Nucl Med 2012;42:190.